[PDF][PDF] Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors
The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase
receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation …
receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation …
Therapeutic developments in pancreatic cancer
ZI Hu, EM O'Reilly - Nature Reviews Gastroenterology & Hepatology, 2024 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …
lethal human malignancies. Much is known regarding the biology and pathophysiology of …
Exposure to fine particulate air pollution is associated with endothelial injury and systemic inflammation
CA Pope III, A Bhatnagar, JP McCracken… - Circulation …, 2016 - Am Heart Assoc
Rationale: Epidemiological evidence indicates that exposures to fine particulate matter air
pollution (PM2. 5) contribute to global burden of disease, primarily as a result of increased …
pollution (PM2. 5) contribute to global burden of disease, primarily as a result of increased …
Targeting the EGFR signaling pathway in cancer therapy
P Seshacharyulu, MP Ponnusamy… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Cancer is a devastating disease; however, several therapeutic advances have
recently been made, wherein EGFR and its family members have emerged as useful …
recently been made, wherein EGFR and its family members have emerged as useful …
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada …
MJ Moore, D Goldstein, J Hamm, A Figer… - Journal of clinical …, 2007 - ascopubs.org
Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …
[HTML][HTML] Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition
TM Gorges, I Tinhofer, M Drosch, L Röse, TM Zollner… - BMC cancer, 2012 - Springer
Abstract Background Circulating tumour cells (CTCs) have shown prognostic relevance in
metastatic breast, prostate, colon and pancreatic cancer. For further development of CTCs …
metastatic breast, prostate, colon and pancreatic cancer. For further development of CTCs …
Advanced pancreatic carcinoma: current treatment and future challenges
A Stathis, MJ Moore - Nature reviews Clinical oncology, 2010 - nature.com
Pancreatic adenocarcinoma is the most lethal of the solid tumors and the fourth leading
cause of cancer-related death in North America. Most patients present with locally advanced …
cause of cancer-related death in North America. Most patients present with locally advanced …
Epigenetic and transcriptional control of the epidermal growth factor receptor regulates the tumor immune microenvironment in pancreatic cancer
Although immunotherapy has revolutionized cancer care, patients with pancreatic ductal
adenocarcinoma (PDA) rarely respond to these treatments, a failure that is attributed to poor …
adenocarcinoma (PDA) rarely respond to these treatments, a failure that is attributed to poor …
Genetics and biology of pancreatic ductal adenocarcinoma
AF Hezel, AC Kimmelman, BZ Stanger… - Genes & …, 2006 - genesdev.cshlp.org
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the
United States with a median survival of< 6 mo and a dismal 5-yr survival rate of 3%–5%. The …
United States with a median survival of< 6 mo and a dismal 5-yr survival rate of 3%–5%. The …
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group …
PA Philip, J Benedetti, CL Corless, R Wong… - Journal of clinical …, 2010 - ascopubs.org
Purpose Patients with advanced pancreas cancer present with disease that is poorly
responsive to conventional therapies. Preclinical and early clinical evidence has supported …
responsive to conventional therapies. Preclinical and early clinical evidence has supported …